Akoya Biosciences, Inc. (AKYA)
NASDAQ: AKYA · Real-Time Price · USD
2.850
-0.050 (-1.72%)
Oct 29, 2024, 4:00 PM EDT - Market closed
Akoya Biosciences Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Akoya Biosciences stock have an average target of 6.08, with a low estimate of 3.00 and a high estimate of 9.00. The average target predicts an increase of 113.33% from the current stock price of 2.85.
Analyst Consensus: Buy
* Price targets were last updated on Aug 13, 2024.
Analyst Ratings
The average analyst rating for AKYA stock from 9 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | May '24 | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 4 | 4 | 4 | 2 | 2 | 2 |
| Hold | 1 | 1 | 1 | 4 | 4 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 9 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Maintains $6 → $4 | Buy | Maintains | $6 → $4 | +40.35% | Aug 13, 2024 |
| Morgan Stanley | Morgan Stanley | Buy → Hold Downgrades $4 → $3 | Buy → Hold | Downgrades | $4 → $3 | +5.26% | Aug 6, 2024 |
| BTIG | BTIG | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Aug 6, 2024 |
| Craig-Hallum | Craig-Hallum | Strong Buy Maintains $7.5 → $7 | Strong Buy | Maintains | $7.5 → $7 | +145.61% | Aug 6, 2024 |
| JP Morgan | JP Morgan | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Aug 6, 2024 |
Financial Forecast
Revenue This Year
99.98M
from 96.63M
Increased by 3.46%
Revenue Next Year
120.64M
from 99.98M
Increased by 20.67%
EPS This Year
-1.04
from -1.43
EPS Next Year
-0.55
from -1.04
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 106.2M | 142.8M | 162.4M | ||
| Avg | 100.0M | 120.6M | 138.1M | ||
| Low | 93.5M | 106.8M | 113.8M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 9.9% | 42.8% | 34.6% | ||
| Avg | 3.5% | 20.7% | 14.5% | ||
| Low | -3.3% | 6.8% | -5.7% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.90 | -0.40 | -0.04 | ||
| Avg | -1.04 | -0.55 | -0.34 | ||
| Low | -1.16 | -0.77 | -0.61 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.